Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight in nine months, substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound, and her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide, Chen writes.